2024
Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis
Romano P, Busti M, Billato I, D’Amico F, Marchegiani G, Pelizzaro F, Vitale A, Cillo U. Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis. BJS Open 2024, 8: zrad158. PMID: 38323881, PMCID: PMC10848305, DOI: 10.1093/bjsopen/zrad158.Peer-Reviewed Original ResearchConceptsBarcelona Clinic Liver CancerTrans-arterial chemoembolizationDisease-free survivalBarcelona Clinic Liver Cancer-A patientsBenefits of LRLiver resectionRadiofrequency ablationHepatocellular carcinomaOS benefitOverall survivalA patientsBarcelona Clinic Liver Cancer ABarcelona Clinic Liver Cancer stageDisease-free survival benefitRisk ratioOutcomes of LRMeta-analysisComparative cohort studyCase-control studyChina Biological Medicine DatabaseHCC patientsCohort studyPrimary outcomeNewcastle-OttawaQuality of studies
2021
Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization
Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization. In Vivo 2021, 35: 3261-3270. PMID: 34697157, PMCID: PMC8627740, DOI: 10.21873/invivo.12621.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationTrans-arterial chemoembolizationNeuroendocrine tumorsColorectal carcinomaIntrahepatic cholangiocarcinomaLipiodol depositionWashout rateContrast-enhanced magnetic resonanceMetastatic liver tumorsColorectal carcinoma tumorsLiver metastasesHepatic metastasesTumor responseTarget lesionsRetrospective analysisLiver tumorsSmall tumorsChemoembolizationCarcinoma tumorsTumorsExponential washoutCarcinomaTomography imagingWashoutCholangiocarcinomaLipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinoma
2020
Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update
Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers 2020, 12: 791. PMID: 32224882, PMCID: PMC7226474, DOI: 10.3390/cancers12040791.Peer-Reviewed Original ResearchStage hepatocellular carcinomaSelective internal radiotherapyAdvanced-stage hepatocellular carcinomaTrans-arterial chemoembolizationHepatocellular carcinomaRecent large prospective trialsSimilar disease control rateManagement of HCCEarly-stage hepatocellular carcinomaStage of HCCDisease control rateSystemic treatment optionsLarge prospective trialsLocal disease controlCancer-related morbidityArterial therapyProspective trialImproved tolerabilityPalliative optionControl rateTreatment optionsTherapeutic strategiesDisease controlInternal radiotherapyTolerability
2019
Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases
Fouladi D, Zarghampour M, Pandey P, Pandey A, Varzaneh F, Ghasabeh M, Khoshpouri P, Kamel I. Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases. European Radiology 2019, 30: 291-300. PMID: 31209620, DOI: 10.1007/s00330-019-06289-3.Peer-Reviewed Original ResearchConceptsShort-term response to treatmentResponse to treatmentHepatic colorectal metastasesPredicting response to treatmentColorectal metastasesSystemic chemotherapyPrediction of response to treatmentPercentile of ADCColorectal liver metastasesTrans-arterial chemoembolizationSystemic chemotherapy patientsBaseline ADCNonresponding lesionsRadioembolization patientsMetastatic lesionsLiver metastasesTACE patientsRadioembolizationPatientsChemotherapy patientsInclusion criteriaResponse to different treatmentsMR imagingTACEROI-based
2018
Role of interventional radiology in the management of hepatocellular carcinoma: current status.
Holzwanger DJ, Madoff DC. Role of interventional radiology in the management of hepatocellular carcinoma: current status. Chinese Clinical Oncology 2018, 7: 49. PMID: 30180753, DOI: 10.21037/cco.2018.07.04.Peer-Reviewed Original ResearchConceptsEarly-stage diseaseStage diseaseHepatocellular carcinomaBarcelona Clinic Liver CancerIntermediate-grade diseaseGold standard therapyTrans-arterial chemoembolizationAvailable treatment optionsTreatment of patientsAdequate oncologic controlAdvanced diseaseLiver transplantationPalliative interventionsPerformance statusStandard therapySurgical resectionGrade diseaseOncologic controlLiver functionTreatment optionsRadiofrequency ablationEffective therapyLiver cancerBetter outcomesClinical practice
2016
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization
Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. European Radiology 2016, 27: 526-535. PMID: 27277261, PMCID: PMC5470590, DOI: 10.1007/s00330-016-4445-9.Peer-Reviewed Original ResearchConceptsMedian overall survivalPortal venous thrombosisAdvanced-stage hepatocellular carcinomaConventional TACEDEB-TACEHepatocellular carcinomaOverall survivalAdverse eventsBeads TACEDrug-eluting bead transcatheter arterial chemoembolizationConventional trans-arterial chemoembolizationPropensity scoreDrug-eluting beads TACECommon adverse eventsConclusionOur retrospective studyEqual safety profileChild-Pugh classMethodsThis retrospective analysisPortal vein thrombosisPost-embolization syndromeTranscatheter arterial chemoembolizationStage hepatocellular carcinomaTrans-arterial chemoembolizationSub-group analysisArterial chemoembolization
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply